Anti-CENP-B antibodies are associated with prolonged survival in breast cancer

Future Oncology

Volumn 6, Issue 3, 2010, Pages 471-477

  Atalay, Can ^a,b   Dogan, Lutfi ^a   Atalay, Gonca ^c  

^a ANKARA ONCOLOGY HOSPITAL   (Turkey)

^b Biskek Cad Yesiltepe Bloklari   (Turkey)

^c Med Lab Laboratories   (Turkey)

Author keywords

Anti CENP B; Anti SS B; Autoimmunity; Breast cancer; Survival

Indexed keywords

AUTOANTIBODY; CENTROMERE PROTEIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LA ANTIBODY; PROGESTERONE RECEPTOR;

ANTIBODY BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; BREAST NEOPLASMS; CENTROMERE PROTEIN B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 77949436265     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.6     Document Type: Article

References (25)

1. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y: Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann. Rheum. Dis. 60, 433-440 (2001).
2. Atalay C, Atalay G, Yilmaz KB, Altinok M: The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma 52, 32-35 (2005).
3. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM: Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am. J. Pathol. 140, 859-870 (1992).
4. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, Varsamidakis N, Machairas A, Mandrekas D: The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 20, 4351-4353 (2000).
5. Gogas H, Ioannovich J, Dafni U et al.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718 (2006).
6. Blaes F, Klotz M, Huwer H et al.: Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann. Thorac. Surg. 69, 254-258 (2000).
7. Gergely L, Dankó A, Csípõ I et al.: Antibodies against extractable nuclear antigen in non-Hodgkin lymphoma patients. Scand. J. Immunol. 61, 343-346 (2005).
8. Wasserman J, Glas U, Biomgren H: Autoantibodies in patients with carcinoma of the breast: correlation with prognosis. Clin. Exp. Immunol. 19, 417-422 (1975).
9. Fernández-Madrid F, VandeVord PJ, Yang X et al.: Antinuclear antibodies as potential markers of lung cancer. Clin. Cancer Res. 5, 1393-1400 (1999).
10. Briasoulis E, Kamposioras K, Tzovaras V et al.: CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature. Lung Cancer 60, 302-306 (2008).
11. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ: CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J. Cell Biol. 130, 507-518 (1995).
12. Earnshaw WC, Rothfield N: Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma. Chromosoma 91, 313-321 (1985).
13. Tanaka Y, Tachiwana H, Yoda K et al.: Human centromere protein B induces translational positioning of nucleosomes on a-satellite sequences. J. Biol. Chem. 280, 41609-41618 (2005).
14. Vig BK, Latour D, Brown M: Localization of anti-CENP antibodies and alphoid sequences in acentric heterochromatin in a breast cancer cell line. Cancer Genet. Cytogenet. 88, 118-125 (1996).
15. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al.: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18, 574-583 (2000).
16. Ruiz-Arguelles A, Perez-romano B, Llorente L, Alarcon-Segovia D, Castellanos JM: Penetration of anti-DNA antibodies into immature live cells. J. Autoimmun. 11, 547-556 (1998).
17. Rivadeneyra-Espinosa L, Ruiz-Arguelles A: Cell-penetrating anti-native DNA antibodies trigger apoptosis through both the neglect and programmed pathways. J. Autoimmun. 26, 52-56 (2006).
18. Furukawa F, Lyons MB, Lee LA, Coulter SN, Norris DA: Estradiol enhances binding to cultured human keratinocytes of antibodies specific for SS-A/Ro and SS-B/La. Another possible mechanism for estradiol influence of lupus erythematosus. J. Immunol. 141, 1480-1488 (1988).
19. Ansar Ahmed S, Aufdemorte TB, Chen JR, Monroya AI, Olive D, Talal N: Estrogen induces the development of autoantibodies and promotes salivary gland lymphoid infiltrates in normal mice. J. Autoimmun. 2, 543-552 (1989).
20. Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM: Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J. Autoimmun. 8, 575-586 (1995).
21. Rattner JB, Rees J, Whitehead CM et al.: High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin. Invest. Med. 20, 308-319 (1997).
22. Tomonaga T, Matsushita K, Yamaguchi S et al.: Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 63, 3511-3516 (2003).
23. Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EKL, Tan EM: De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin. Exp. Immunol. 125, 3-9 (2001).
24. Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I: The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk. Lymphoma 40, 119-122 (2000).
25. Clark GM, Allred DC, Hilsenbeck SG et al.: Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 57, 5505-5508 (1997).